Quest Diagnostics (DGX) Starts Performing COVID-19 Antibody Testing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Quest Diagnostics (DGX) Tops Q1 EPS by 4c, Revenues Beat
April 22, 2020 6:46 AM EDTQuest Diagnostics (NYSE: DGX) reported Q1 EPS of $0.94, $0.04 better than the analyst estimate of $0.90. Revenue for the quarter came in at $1.82 billion versus the consensus estimate of $1.76 billion.
"We were very pleased with Quest's results in January and February, which were consistent with the full-year guidance we provided in January," said Steve Rusckowski, Chairman, CEO and President. "However, in March, we experienced a material decline in testing volumes due to the COVID-19 pandemic. During the last... More
